Stone Pharmaceutical Group: GLP-1/GIP receptor biased agonist dual-acting peptide injection approved for clinical trials in the United States

The announcement by Stone Pharmaceutical Group states that the group's GLP-1/GIP receptor biased agonist peptide injection has been approved by the U.S. Food and Drug Administration for clinical trials in the United States. This product is expected to be China's first GLP-1/GIP receptor biased agonist to enter the clinical stage, selectively activating the cAMP pathway, significantly reducing -arrestin recruitment, thereby reducing receptor internalization and desensitization, improving efficacy and duration of effect. At the same time, combining the long half-life modification platform technology, this product can achieve deeper and more sustained weight loss effects.